Vivos Inc (RDGL)

[HoneyBager]

https://www.fiercepharma.com/pharma/top-10-ma-deals-2022

“While deal values—and volumes—may have disappointed some in 2022, PwC analysts see some reasons for a potential rebound. For 2023, the team said it expects an “active year” thanks to “ample” corporate cash, the need to fill pipeline gaps at Big Pharmas and “resetting” biotech valuations. Deals in the $5 billion to $15 billion range represent the “sweet spot,” according to the experts, but larger acquisitions could come later in the year.”

Sounds good to me to see a potential buyout if it comes to the table for $10 Billion